Recce Pharmaceuticals Ltd - Asset Resilience Ratio

Latest as of December 2025: 11.64%

Recce Pharmaceuticals Ltd (RCE) has an Asset Resilience Ratio of 11.64% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$237.73K

≈ $168.21K USD Cash + Short-term Investments

Total Assets

AU$2.04 Million

≈ $1.44 Million USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Recce Pharmaceuticals Ltd's Asset Resilience Ratio has changed over time. Check how strategically is Recce Pharmaceuticals Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Recce Pharmaceuticals Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Recce Pharmaceuticals Ltd worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$0.00	0%
Short-term Investments	AU$237.73K	11.64%
Total Liquid Assets	AU$237.73K	11.64%

Asset Resilience Insights

Moderate Liquidity: Recce Pharmaceuticals Ltd has 11.64% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Recce Pharmaceuticals Ltd Industry Peers by Asset Resilience Ratio

Compare Recce Pharmaceuticals Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	10.93%
Shanghai Allist Pharmaceuticals Co. Ltd. A SHG:688578	Biotechnology	21.11%
Tubize-Fin BR:TUB	Biotechnology	0.05%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	57.90%
TELIX Pharmaceuticals Ltd AU:TLX	Biotechnology	32.29%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	Biotechnology	39.07%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%

Annual Asset Resilience Ratio for Recce Pharmaceuticals Ltd (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Recce Pharmaceuticals Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-06-30	1.91%	AU$236.63K ≈ $167.43K	AU$12.41 Million ≈ $8.78 Million	-1.36pp
2024-06-30	3.26%	AU$207.86K ≈ $147.07K	AU$6.37 Million ≈ $4.51 Million	+1.42pp
2023-06-30	1.84%	AU$47.00K ≈ $33.26K	AU$2.56 Million ≈ $1.81 Million	+1.68pp
2022-06-30	0.16%	AU$20.10K ≈ $14.22K	AU$12.62 Million ≈ $8.93 Million	-59.27pp
2018-06-30	59.43%	AU$679.72K ≈ $480.95K	AU$1.14 Million ≈ $809.27K	-15.02pp
2017-06-30	74.45%	AU$1.09 Million ≈ $771.56K	AU$1.46 Million ≈ $1.04 Million	--
2016-06-30	0.00%	AU$0.00 ≈ $0.00	AU$3.72 Million ≈ $2.63 Million	--

pp = percentage points

About Recce Pharmaceuticals Ltd

AU:RCE Australia Biotechnology

Market Cap

$79.46 Million

AU$112.30 Million AUD

Market Cap Rank

#20078 Global

#659 in Australia

Share Price

AU$0.38

Change (1 day)

+0.00%

52-Week Range

AU$0.35 - AU$0.71

All Time High

AU$1.68